Markets
Donald Trump Campaigns For President In Arizona's Prescott Valley
US Republican presidential nominee, former President Donald Trump dances during a campaign rally (Rebecca Noble/Getty Images)
Big League Choose

The calculus behind betting on a Trump win: his stock, or prediction markets?

DJT has not been a particularly reliable barometer for Trump’s perceived odds of winning the election, but that doesn’t necessarily mean it’s a bad bet.

Luke Kawa

Shares of Trump Media & Technology Group spiked 18.5% to open the week, continuing a ridiculous run that’s seen the stock gain about 150% since its September 23 low. 

The rise has coincided with a big improvement in Republican nominee Donald Trump’s chances of winning the presidential election — at least in the eyes of prediction markets.

Over in the options market, traders are betting that the recent volatility is just a warm-up for what awaits once the vote plays out. The stock is priced to move roughly 26% each day in the week of the election. If we presume much of the volatility premium is tied to the vote (a safe assumption!) then we’re probably looking at an election-aftermath move in the neighborhood of double that being embedded in these options.

This raises the question: what are the relative merits of betting on a Trump win using prediction markets compared to the stock or options markets, now that all these choices have effectively amalgamated?

The payout structure on platforms that allow you to bet on election results is relatively straightforward. In this instance, a wager that Trump would win the presidential election would pay out at about an 84% return if successful, based on current odds.

Now, let’s turn to betting on Trump using the proxy of his stock. Looking at its closing price of almost $30 on Monday, shares of Trump Media & Technology Group would need to rally to $54 to match what’s on offer from prediction markets — a closing level achieved only four times since the ticker debuted on March 26.

The options payout structure is a lot more complex, and we’ll use some simplifying assumptions (via Bloomberg) that indicate about a 55% rally in the stock required to generate that same 84% return via the November 8 contract with the highest open interest (assuming you’re holding to expiry). These options are so expensive — because the stock is expected to move so much on the election result — that it diminishes the potential for massive gains. Options that expire before the election, by comparison, are much cheaper.

All I’ve done so far is outline the levels that different financial instruments would need to get in order to equal the return that’s achievable in prediction markets. That doesn’t answer the questions of why or whether DJT would rally that much in the first place.

DJT has not been a particularly reliable barometer for Trump’s perceived odds of winning the election. Yes, the two have certainly moved higher hand-in-hand recently. Shares also got a bump after the mid-July attempted assassination of the former president. But the stock didn’t rise after President Joe Biden’s brutal debate performance

And even as Trump’s election prospects steadied and improved to above 50% from mid-August to early September, DJT lost more than a quarter of its value.

That’s because while this is also a temperature check on Trump’s election prospects, it is also a company — a company that loses a lot of money, seeing $16 million in red ink as of its most recent quarter on revenues of less than $1 million.

But it seems safe to say that a world in which Trump wins the election is much better for the stock (and the company) compared to one in which he fails to regain the presidency. To play devil’s advocate, I guess you could benchmark the stock’s peak ($66.22) and suggest that if it were able to trade there without Trump being POTUS, then it could certainly trade there in a hurry if he were. One can imagine a world in which Truth Social has more cachet and monetization potential if government officials are highly encouraged and/or mandated to release official statements there before anywhere else, for instance.

But it seems likely that you’d also need something of a temporary, collective suspension of disbelief for this to play out, given Truth Social’s lack of operational success to date. Of course, if things in markets aren’t efficient when people get really excited about a struggling brick-and-mortar retailer, there’s no reason to expect rational price action when one of the biggest cults of personality in the history of American politics intersects with market momentum.

This is ultimately about judging the relative merits of a bet in which you, in theory, have a 53% chance of making an +80% return if you’re right versus other bets where you have a ??? (joint probability of Trump winning and DJT shares being meme-worthy) chance of making a ??? return. 

From this perch, it really doesn’t look too efficient to be using DJT or any of its derivatives to bet on a Trump win — not when a much less convoluted and substantial return (through platforms that can now be used by Americans!) is available. 

But if you’re thinking that a Trump win will get fully priced before the election results, that’s a completely different story.

DJT and its derivatives look like a much better way to bet on the idea that more people will think Trump will win the election than they are vehicles to benefit from Trump actually winning the election.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.